Subject: Successful completion of USFDA Audit for A-31 Mumbai Unit with No Observations.

Dear Stakeholders,

We are writing to inform you that we have been successfully audited by the USFDA from 13th to 17th March-23 for our **Mumbai Clinical A-31 facility**. This was an on-site audit and we are glad to inform you that USFDA auditors have cleared the audit with **No Objectionable Observations (No 483 observations).** There were 3 projects which were selected for this audit and were cleared without any observations.

This was the 42nd USFDA audit successfully cleared by Accutest Research Laboratories Pvt. Ltd.

We also cleared a remote audit by USFDA for our Ahmedabad Clinical facility in the month of Oct 2022 without any observation. The audit report is attached with this email for your kind reference.

To achieve this positive outcome we have implemented several changes in our organization (people) and have upgraded several internal processes.

We are now looking with a fresh perspective after a temporary blip (WHO audit in June 2022) for which we have implemented a CAPA which includes a permanent closure of the pathology department. A-31 Clinical facility was the only unit of Accutest Research Laboratories Pvt. Ltd. impacted by WHO findings; this unit was successfully audited by USFDA. We are expecting an audit by WHO in June 2023 and are confident that we will clear all the points raised in the last audit.

We want to assure you that we will continue to maintain the high-quality standards that we have demonstrated for the last 25 years.

Please let us know if there is anything we can do to improve your experience of working with us.

Dr. Santosh Joshi

CEO

ACCUTEST RESEARCH LABORATORIES (I) PRIVATE LIMITED

Accutest Research Laboratories (I) Pvt. Ltd.
A - 31, MIDC, TTC Industrial Area, Khairne, Navi Mumbai - 400 709. Maharashtra, India
Tel. : 91-22-2778 0718 / 19 / 21. Mob.: 9967642889 Fax : 91-22-2778 0720 Website : www.accutestglobal.com
E-mail : business@accutestglobal.com / CIN : U24239MH2001PTC131153.